Skip to main content

Table 4 Hazard ratios for the acquisition and clearance of MDRAB

From: Acquisition and clearance of multidrug resistant Acinetobacter baumannii on healthy young adults concurrently burned in a dust explosion in Taiwan: the implication for antimicrobial stewardship

Variable

Univariate analysis

Multivariate analysis

acquisition hazard ratio, (95% CI)

P value

clearance hazard ratio, (95% CI)

P value

acquisition hazard ratio, (95% CI)

P value

clearance hazard ratio, (95% CI)

P value

Baseline transition rate (/day)

    

0.005

 

0.01

 

 Age

0.90 (0.74–1.09)

0.271

1.10 (0.91–1.33)

0.318

    

 Sex

0.41 (0.08–1.98)

0.268

2.38 (0.49–11.46)

0.281

    

Cumulative antibiotic exposure (days of therapy)

 Carbapenem

1.09 (1.02-1.16) b

0.007

1.0 (0.94–1.06)

0.908

1.08 (1.01-1.16) b

0.020

1.07 (0.99–1.17)

0.083

 Glycopeptide

1.04 (0.98–1.11)

0.209

1.1 (1.0–1.2)

0.140

-

 

-

 

 Non-carbapenem Beta-lactam

0.9 (0.78–1.100)

0.340

1.19 (1.05-1.34) b

0.024

0.97 (0.81–1.15)

0.711

1.25 (1.07-1.46) b

0.004

 Antifungus

1.02 (0.94–1.1)

0.594

1.1 (0.97–1.1)

0.196

-

 

-

 

 Miscellaneous

a

 

a

 

-

 

-

 
  1. aindicated too small sample size for model estimation
  2. bHazard ratio with statistical significance